Wyeth has revised the summary of product characteristics for Prostap SR (leuprorelin acetate) 3.75mg depot injection. The licensed indication has been extended to include the pre-operative management of uterine fibroids to reduce their size and associated bleeding. The recommended dose for this indication is 3.75mg, administered as a single subcutaneous or intramuscular injection every month, usually for 3-4 months but for a maximum of six months. Further statements relating to pre-operative treatment of fibroids, age-related bone loss and submucous fibroids, have been added to the special warnings and precautions for use section under the heading "Women". Under general undesirable effects, the statement "Thrombocytopenia and leucopenia have been reported rarely" has been added. Hypertension and palpitations have been added to the list of undesirable effects in women. The components of the sterile vehicle have been listed and in-use stability information reworded. The product should not be stored above 25C.